Get the Message to Guests: Your Properties are Safe and Sound

Driven by consumer desires for new experiences, innovative technologies and environmental impacts – travel is changing. Host Sarah Dandashy explores the technologies and logistics that power travel and the brands that build unforgettable experiences.

 

On this episode of Say Yes To Travel, host Sarah Dandashy sits down with Hermann Elger, the executive vice president of travel, entertainment, and health security at Sharecare, the digital health company that helps people manage all their health in one place. Dandashy has been interviewing hospitality professionals worldwide who have been fighting to stay afloat during the pandemic, talking about the past year and where the hospitality industry goes from here.

“Just letting the traveler know that everyone in the city is on the same page from a health and security perspective.” -Hermann Elger

Elger’s father worked in the hotel industry, so diving into the career path seemed natural. He served as general manager for Baccarat Hotels and Resorts, overseeing operations and the guest experience at luxury properties such as The St. Regis New York and Montage Beverly Hills. He also spent 18 years with The Ritz-Carlton Hotel Company, where he supported the development of new hotels as an opening team leader for The Ritz-Carlton Aspen Highlands, Philadelphia, Dubai, and Kuala Lumpur.

Sharecare popped up on my radar when Los Angeles became the first Sharecare verified city in the United States. This verification process aims to unify messaging from hotel to consumers that the hotels in the area are clean and safe.

“It is a way to build that consistency and consistent messaging from a marketing perspective,” Elger said. “Just letting the traveler know that everyone in the city is on the same page from a health and security perspective.”

Say Yes To Travel has a New Episode Every Thursday!

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

 

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More